Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | APP | P05067 | 1/20 | 0.53 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | F7 | P08709 | 1/20 | 0.52 |
| ▸ | F3 | P13726 | 1/20 | 0.52 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nikethamide SCHEMBL246456 | 1.00 | HTT (0.65) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL2477607 | 0.98 | HTT (0.63) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL28425770 | 0.98 | HTT (0.63) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL11145071 | 0.95 | HTT (0.64) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL5964875 | 0.92 | F7 (0.67) | HTTALDH1A1LMNAKDM4EHPGD | |
| Nikethamide SCHEMBL9541686 | 0.92 | HTT (0.57) | HTTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL10599239 | 0.89 | HTT (0.57) | HTTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL14855190 | 0.89 | HTT (0.61) | HTTALDH1A1LMNAKDM4EHPGD | |
| SCHEMBL28527737 | 0.86 | HTT (0.57) | HTTALDH1A1LMNAKDM4EGAA | |
| SCHEMBL30476608 | 0.84 | HTT (0.63) | HTTALDH1A1LMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | claimed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | claimed |
| EP-3570341-B1 | WHITE ORGANIC ELECTROLUMINESCENT DEVICE AND PREPARATION METHOD THEREFOR | CHANGCHUN INST APPLIED CHEMISTRY CAS (CN) | 2022-08-03 | — | — | EP | claimed |
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250302753-A1 | Membrane-forming composition, membrane-like composition, and use of same | TOWA PHARMACEUTICAL CO., LTD (JP) | 2025-10-02 | — | — | US | disclosed |
| EP-4527411-A1 | MEMBRANE-FORMING COMPOSITION, MEMBRANE-LIKE COMPOSITION, AND USE OF SAME | TOWA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-26 | — | — | EP | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| US-20240424171-A1 | BIOCOMPATIBLE COMPOSITE MATERIAL AND METHOD OF MAKING THE SAME | BIO PROTECTANT TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240285421-A1 | Polymer Coatings Containing Drug Powder Of Controlled Morphology | MICELL MEDTECH INC. (US) | 2024-08-29 | — | — | US | disclosed |
| CN-118401373-A | Photoactivated resin composition and use thereof in 3D printing | 上阿尔萨斯大学 | 2024-07-26 | — | — | CN | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-116057057-A | Conjugates of alpha 2-adrenoceptor subtype C (alpha-2C) antagonists and TASK1/3 channel blockers for the treatment of sleep apnea | 拜耳公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20230129807-A1 | Drug Eluting Balloon | ORBUSNEICH MEDICAL PTE LTD. (SG) | 2023-04-27 | — | — | US | disclosed |
| US-11559671-B2 | Drug eluting balloon | ORBUSNEICH MEDICAL PTE. LTD. (SG) | 2023-01-24 | — | — | US | disclosed |
| US-11534375-B2 | Solvent-free method of encapsulating a hydrophobic active | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2022-12-27 | — | — | US | disclosed |
| EP-2658527-B1 | NANOPARTICLE AND SURFACE-MODIFIED PARTICULATE COATINGS, COATED BALLOONS, AND METHODS THEREFORE | MICELL TECHNOLOGIES INC (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11497834-B1 | Supercritical method of making a biocompatible composite implant | Bio Protectant Technologies, Inc. (US) | 2022-11-15 | — | — | US | disclosed |
| CN-115315222-A | Treatment of cardiac tissue using pulsed electric fields | 盖能适治疗股份有限公司 | 2022-11-08 | — | — | CN | disclosed |
| US-11426494-B2 | Stents having biodegradable layers | MT Acquisition Holdings LLC (US) | 2022-08-30 | — | — | US | disclosed |
| US-11369498-B2 | Stent and stent delivery system with improved deliverability | MT Acquisition Holdings LLC (US) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | HTT 6/4885ALDH1A1 1386/4885LMNA 680/4885 |
| US-20250302753-A1 | Membrane-forming composition, membrane-like composition, and use of same | STOM, LIPA, MGLL | HTT 1489/4885ALDH1A1 4450/4885LMNA 1713/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | HTT 6/4885ALDH1A1 1386/4885LMNA 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.